Skip to content
Search
AI Powered
Human content, AI powered search.
Latest Stories

IGD launches GLP-1 insight programme to help food industry businesses

IGD launches GLP-1 insight programme to help food industry businesses

IGD launches GLP-1 insight programme for food sector

Image by IGD
Pooja Shrivastava
By Pooja ShrivastavaJan 23, 2026
Pooja Shrivastava
A passionate journalist with about a decade of experience, Pooja has developed a strong hold on the UK grocery retail sector. From exploring legislative changes, supply chain shifts, consumer buying habits, trends to retail crime, her work is driven by a deep belief in investigating, finding the truth and telling authentic unbiased stories. Be it convenience pathbreakers, wholesale trendsetters or Post Office Horizon scandal victims, Pooja has an equal flair for deciphering industries as well as human complexities. At Asian Trader, she aims to bridge the gap between policy, trade, and the shop floor, always keeping a finger on the pulse of what matters most to retailers.
See Full Bio
Follow:

Weight loss medication usage is rising fast, with uptake among UK adults growing from 3.1 per cent in June 2025 to 4.2 per ent in October, more than the number following a vegan diet, states IGD (Institute of Grocery Distribution).

IGD has also captured the effects, with 35% of GLP-1 users eating out less often, 69% eating fewer snacks, and 48% eating fewer meals overall.

To help food industry businesses understand, navigate, and capitalise on the impacts of weight loss medication use, IGD has announced a new insight programme called, ‘IGD Futures: GLP‑1’.

‘IGD Futures: GLP‑1’ is designed to provide a total consumption view of current and future changes in consumer and shopper behaviours, household dynamics, and category demand. It also brings together insights on wider GLP-1 impacts, such as global trends and the evolving science and regulations.

The programme uses a mixed methodology approach, incorporating longitudinal diary tracking of GLP-1 users, qualitative research into behaviours and sentiments, social listening in the UK and US, and global horizon scanning of industry responses and innovation.

Tom Wakeman, Insight Director at IGD, commented: “Consistently, the industry tells us they need to understand who is changing, how they are changing, and where the opportunities are.

“We have structured this programme to help businesses turn behaviour change into commercial advantage. Our unique holistic approach reveals what is shifting, why it is shifting, and what actions will unlock value.

"Powered by deep insight and reliable foresight, this programme projects the scale of impact so businesses can stay ahead."

The ‘IGD Futures: GLP‑1’ programme promises a “year‑round flow of GLP-1 intelligence”, including:

  • A detailed picture of GLP‑1 usage, user profiles, and how spend is shifting both in‑home and out‑of‑home into broader lifestyle categories.
  • A holistic view across consideration, active use, tapering, and long‑term lifestyle change beyond current users.
  • Future scenarios of global adoption patterns and shifts.
  • Insight into strategic implications and next steps.
weight loss medicationglp-1

Related News